SCHEMBL1777877

SCHEMBL1777877

CCOC(=O)n1nc(NC(=O)c2ccc(N3CCN(C)CC3)cc2NC(=O)C2CCOCC2)c2cc(C(=O)OC(C)(C)C)sc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE7A Q13946 6/20 0.43
INSR P06213 9/20 0.41
ALK Q9UM73 9/20 0.41
IGF1R P08069 6/20 0.41
AURKA O14965 2/20 0.40
AURKB Q96GD4 2/20 0.40
PLK4 O00444 1/20 0.40
DAPK3 O43293 1/20 0.40
JAK2 O60674 1/20 0.40
MAP4K4 O95819 1/20 0.40
ABL1 P00519 1/20 0.40
NTRK1 P04629 1/20 0.40
PRKCG P05129 1/20 0.40
LCK P06239 1/20 0.40
FYN P06241 1/20 0.40
CSF1R P07333 1/20 0.40
LYN P07948 1/20 0.40
RET P07949 1/20 0.40
MET P08581 1/20 0.40
ROS1 P08922 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1781442 0.92 PDE7A (0.45) PDE7AINSRALKIGF1RAURKA
SCHEMBL1779953 0.89 AURKA (0.46) PDE7AINSRALKIGF1RAURKA
SCHEMBL1778668 0.87 PDE7A (0.41) PDE7AINSRALKIGF1RAURKA
SCHEMBL1780872 0.87 KMT2A (0.44) KDM4ELMNAMAPTHDAC3HDAC1
SCHEMBL1778870 0.85 CSF1R (0.40) PDE7AINSRALKIGF1RAURKA
SCHEMBL1781437 0.85 BTK (0.45) INSRALKIGF1RAURKABTK
SCHEMBL1777250 0.84 IGF1R (0.44) PDE7AINSRALKIGF1RAURKA
SCHEMBL1779266 0.84 WDR5 (0.37) INSRALKIGF1RAURKAAURKB
SCHEMBL1777894 0.84 ALK (0.43) PDE7AINSRALKIGF1RAURKA
SCHEMBL1780302 0.84 WDR5 (0.35) PDE7AINSRALKIGF1RAURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1904503-B1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES SRL (IT) 2013-11-06 EP disclosed
US-7943654-B2 1H-thieno[2,3-c]pyrazole compounds useful as kinase inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2011-05-17 US disclosed
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2009-06-11 US disclosed
EP-1904503-A1 1H-THIENO[2,3-C]-PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.r.l. (IT) 2008-04-02 EP disclosed
WO-2007009898-A1 1H-THIENO[2,3-C]PYRAZOLE COMPOUNDS USEFUL AS KINASE INHIBITORS NERVIANO MEDICAL SCIENCES S.R.L. (IT) 2007-01-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090149457-A1 1H-Thieno[2,3-c]Pyrazole Compounds Useful as Kinase Inhibitors CCNH, PDK1, MAP3K5 PDE7A 2291/4885INSR 1010/4885ALK 423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.